

Hybridomas are obtained by fusing normal B lymphocytes with a myeloma (tumor B cell line). Thus, a cloned hybridoma cell line has an unlimited capacity to grow in culture, producing immunoglobulin molecules with identical structure and antigen specificity, termed monoclonal antibodies (mAbs), which may have a wide variety of applications.

BACKGROUND

Monoclonal antibodies specific for molecules expressed by leukocytes, termed "leukocyte differentiation antigens" (CD) are used in biomedical research, as well as for the detection of biomarkers with diagnostic, prognostic and/or therapeutic interest in the clinical management of different diseases. Our clone UP-H2 was validated in the panel for the diagnosis of a subset of acute myeloid leukemias according to Euroflow, a consortium funded by the European Union to define suitable markers for hematopoietic malignancies.

CATALOGUE


Hybridoma cell lines currently available for licensing include the following:

CLONE	SPECIFICITY	ISOTYPE
HP-1F7	HLA class I	IgG1
HP-3D9	CD94	IgG1
HP-3B1	CD94	IgG2b
HP-3G10	CD161	IgG1
HP-4B3	CD69	IgG1
HP-F1	ILT2 (LIR1, CD85j, LILRB1)	IgG1
HP-MA4	CD158 (KIR2DL1/S1/S3/S5)	IgG2
HP-3E4	CD158 (KIR2DL1/S1/S3/S4/S5)	IgM
UP-D1	CD300f (IREM-1)	IgG1
UP-D2	CD300f (IREM-1)	IgG1
UP-H1	CD300e (IREM-2)	IgG2a
UP-H2	CD300e (IREM-2)	IgG1
UP-R1	CD158f (KIR2DL5)	IgG1

LICENSE CONDITIONS

All our hybridoma cell lines are licensed under the following conditions:

- Worldwide license
- Non-exclusive license
- An up-front payment
- Royalty on Sales
- Without any right to sublicense



COMMERCIAL OPPORTUNITY

All these clones are available for licensing.

CONTACT

Dr Cinta Diez
Technology Transfer Unit
(+34) 93 316 09 13
cinta.diez@upf.edu

KEYWORDS

Hybridoma cell line, monoclonal antibody.

SEE MORE TECHNOLOGIES AT:

knowledge.upf.edu/